Answers are grounded in this paper and cite their sources.
Background: Immunoglobulin E antibody omalizumab is an effective and safe treatment option in patients with chronic urticaria and evidence is lacking in patients with chronic inducible urticaria (CindU). In this study, it was aimed to determine the efficacy of omalizumab in patients with CindU.
No takes yet. Share an insight, caveat, or question.
Aşkın et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: